問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝清昀

Recruiting

List

101Cases

2023-04-01 - 2026-08-30

Phase I

Active
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

  • Condition/Disease

    Malignant Solid Tumors

  • Test Drug

    liquid

Participate Sites
7Sites

Recruiting7Sites

2024-12-26 - 2028-10-20

Phase III

Active
A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib versus Investigator’s Choice in Adult Patients with Relapsed/Refractory Peripheral T-cell Lymphoma

  • Condition/Disease

    Relapsed/Refractory Peripheral T-cell Lymphoma

  • Test Drug

    injective

Participate Sites
8Sites

Recruiting8Sites

2022-07-04 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-08-14 - 2027-07-24

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-10-15 - 2024-06-13

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2025-02-03 - 2029-01-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Injectable frozen powder

Participate Sites
5Sites

Recruiting5Sites

2024-04-10 - 2028-07-25

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-08-01 - 2029-02-08

Phase I

Active
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-902 in Participants with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injective

Participate Sites
3Sites

Recruiting3Sites

2020-10-16 - 2024-04-30

Phase II

Completed
A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination in Patients with Recurrent or Metastatic Solid Tumors

  • Condition/Disease

    Recurrent or metastatic solid tumor

  • Test Drug

    BAY 73-4506 (Regorafenib)Nivolumab

Participate Sites
3Sites

Recruiting3Sites

2024-12-02 - 2027-12-31

Phase I/II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
4Sites

Recruiting4Sites

1 5 6 7 8 9 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB